29
Oct
2020

J&J, AZ Back in the Saddle, Regeneron Moves the Ball Downfield, and a Flurry of Deals

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

AZ’s Muddy Result, Regeneron Cocktail OK’d, and Biogen, Sage Bet Big on Depression
Moderna, Pfizer Nail COVID-19 Vaccines. Now Comes the Hard Part
Pfizer, BioNTech’s Watershed Moment, Lilly Antibody Gets EUA, & The Rebuilding Begins
Reflections from a Wisconsin Boy